Navigation Links
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Date:7/16/2008

- Expanded Collaboration Supports Pivotal Phase 2b Clinical Trials of First Potential Therapy to Address an Underlying Cause of Cystic Fibrosis -

SOUTH PLAINFIELD, N.J. and BETHESDA, Md., July 16 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced the expansion of an existing collaboration to support development of PTC124, the PTC's new investigational oral drug for the treatment of cystic fibrosis (CF) caused by nonsense mutations. PTC will receive up to $25 million from CFFT in support of key Phase 2b clinical trials for PTC124 in CF.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are pleased to expand our collaboration with PTC Therapeutics on the development of the therapy PTC124," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "The encouraging data from the Phase 2a studies indicate that PTC may become a very important drug for the treatment of CF in the 10 percent of patients who carry nonsense mutations. These exciting results lead us to believe PTC124 has the potential to be one of the first oral drugs on the market to address the basic defect in cystic fibrosis."

"We are honored both to receive this award and to continue our productive collaboration with the Foundation," stated Stuart W. Peltz, Ph.D., president and chief executive officer of PTC Therapeutics. "The significant progress that we have made with PTC124 is a result of our unique drug discovery approach as well as the extraordinary support that we have received from the physician, patient, advocacy and regulatory communities. We look forward to initiating registration-directed studies of PTC124 for nonsense-mutation- mediated CF within the next few months."

In June 2008, PTC announced encouraging new
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Board Changes
5. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Texas, Aug. 3, 2015  Luminex Corporation (NASDAQ: ... quarter ended June 30, 2015.  Financial and operating highlights ... Increased second quarter 2015 revenue by 6 percent to ... , Grew second quarter 2015 assay revenue by 22 ... quarter of 2014. , Increased Q2 2015 royalty ...
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... CHICAGO , August 3, 2015 ... Report 2015 market research with 2020 forecasts as ... the healthcare and medical devices intelligence collection of ... medical simulation market with 2020 forecasts spread across ... supported with 170 tables and figures is now ...
Breaking Medicine Technology:Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6
... 2011 ImpactRx, the pioneer in measuring the ... the rollout of POP 2.0, a proprietary, event-triggered ... physician panels. Triggered by events already ... POP (Point-of-Promotion/Point-of-Prescribing) surveys enable ImpactRx to uniquely capture ...
... Ore., June 27, 2011 Bend Research Inc. ( www.bendresearch.com ... named a new president. Jim Nightingale, who ... fourth president in the firm,s 36-year history. ... capacity as Bend Research Chief Executive Officer (CEO) and chairman ...
Cached Medicine Technology:Enhanced POP 2.0 Provides Custom Insight Into the Physician's Mindset at the Point of Promotion and Prescribing 2Bend Research Inc. Names New President 2
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health Food ... its website. , “Our ‘Ask a Nutritionist’ feature on our website is a free ... said Liza Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food Grocers’ ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Journal Constitution, the new Lifetime reality series, “Atlanta Plastic” is getting attention for ... receives plastic surgery, with its predominantly African-American cast of doctors and patients. Beverly ...
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor & Kantor, LLP announced ... firm’s client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement ... residential treatment for bulimia, depression and other mental health problems. , According to ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the ... to offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists ... , Annually, more than 8.6 million adverse drug events are reported in the ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... services to help patients in need. Most people know that general health emergencies, such ... Unfortunately, a fewer amount of people know where to turn to during a dental ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... ), an online investment newsletter focused on long-term growth ... of several biotech stocks, including Amgen (Nasdaq: ... Celgene (Nasdaq: CELG ), Genzyme (Nasdaq: ... VRTX ).All paid and trial subscribers to BullMarket.com can ...
... has been proclaimed as "World Glaucoma Day" by glaucoma ... Health Organization, more than five million people, many of ... Most lacked the opportunity to get tested for Earlier ... sight. Dr. Robert Welsh, a Rotarian, a world-renowned Eye ...
... System enhances speed and accuracy of patient orders ... insurance plan and medical conditionRICHMOND, Va., March 12 ... provider of billable home medical supplies, announced the ... to enhance speed and accuracy of patient medical ...
... workforce planningWASHINGTON, March 12 Health system reform cannot be successful without ... Steven A. Wartman, president and CEO of the Association of Academic Health ... W orkforc e I ... lth Care Re form ...
... Not Listed on Product Labels Due to Weak Regulatory ... and "pure," dozens of top-selling children,s bath products are ... to product test results released today by the ... were not disclosed on product labels because contaminants are ...
... March 12 For the past three decades, employers ... care costs. Now some are pinning their hopes on ... link high-deductible health insurance plans with tax-favored accounts. The ... titled "Outlook for Consumer/Patient Engagement in Health Care -- ...
Cached Medicine News:Health News:BullMarket.com Updates Outlook on Biotech Stocks 2Health News:Welsh 'Self-Test' to Help Cure Glaucoma on World Glaucoma Day 2Health News:Home Care Delivered, Inc. Launches Proprietary Insurance Payer Management System 2Health News:Health Reform Must Include Health Workforce, AAHC President Tells Congress 2Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 2Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 3Health News:EBRI Policy Forum: Consumer/Patient Engagement in Health Care - 30 Years On 2
... Designed To Be Used With The Gills ... On The Cornea For Making Limbal Relaxing Incisions., ... The Gills Nomograms. 6mm & 8mm Chord Length ... Relaxing Incisions.5mm Inner Circle Assists In Sizing A ...
... This System Is Designed To Manually Dilate ... Efficacy. The Bimanual Technique Maximizes Safety By ... Parallel, Rather Than Perpendicular, To The Plane ... Risk Of Inadvertent Capsule Tears. Pupil Stretching ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Unique Reversible Speculums Designed To Rest ... Flipping The Speculums Over, Allowing Eyelids ... Fissures To The Widest Possible Aperture.,Open ... Unobstructed Around-The-Clock Access To The Globe ...
Medicine Products: